# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain...
Stifel analyst Bradley Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $8 to ...
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that the Comp...
Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Bene...
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...